Bo Dong
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo Dong has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
- Yadi Wu
Department of Pharmacology & Nutritional Sciences, University of Kentucky School of Medicine, Lexington, Kentucky
2 shared publications Zhaoping Qiu
Department of Pharmacology and Nutritional Sciences, University of Kentucky School of Medicine, Lexington, KY, United States
1 shared publication
Latest Publications
- Open Access
- 14 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (20) , 11062
Epigenetic Regulation and Post-Translational Modifications of SNAI1 in Cancer Metastasis
SNAI1, a zinc finger transcription factor, not only acts as the master regulator of epithelial-mesenchymal transition (EMT) but also functions as a driver of cancer progression, including cell invasion, survival, immune regulation, stem cell properties, and metabolic regulation. The regulation of SNAI1 occurs at the transcriptional, translational, and predominant post-translational levels including phosphorylation, acetylation, and ubiquitination. Here, we discuss the regulation and role of SNAI1 in cancer metastasis, with a particular emphasis on epigenetic regulation and post-translational modifications. Understanding how signaling networks integrate with SNAI1 in cancer progression will shed new light on the mechanism of tumor metastasis and help develop novel therapeutic strategies against cancer metastasis.
- 14 October 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (20) , 11062
Open AccessEpigenetic Regulation and Post-Translational Modifications of SNAI1 in Cancer Metastasis
SNAI1, a zinc finger transcription factor, not only acts as the master regulator of epithelial-mesenchymal transition (EMT) but also functions as a driver of cancer progression, including cell invasion, survival, immune regulation, stem cell properties, and metabolic regulation. The regulation of SNAI1 occurs at the transcriptional, translational, and predominant post-translational levels including phosphorylation, acetylation, and ubiquitination. Here, we discuss the regulation and role of SNAI1 in cancer metastasis, with a particular emphasis on epigenetic regulation and post-translational modifications. Understanding how signaling networks integrate with SNAI1 in cancer progression will shed new light on the mechanism of tumor metastasis and help develop novel therapeutic strategies against cancer metastasis.
- Open Access
- 27 November 2020
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Tackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer
Epithelial-mesenchymal Transition (EMT) is a de-differentiation process in which epithelial cells lose their epithelial properties to acquire mesenchymal features. EMT is essential for embryogenesis and wound healing but is aberrantly activated in pathological conditions like fibrosis and cancer. Tumor-associated EMT contributes to cancer cell initiation, invasion, metastasis, drug resistance and recurrence. This dynamic and reversible event is governed by EMT-transcription factors (EMT-TFs) with epigenetic complexes. In this review, we discuss recent advances regarding the mechanisms that modulate EMT in the context of epigenetic regulation, with emphasis on epigenetic drugs, such as DNA demethylating reagents, inhibitors of histone modifiers and non-coding RNA medication. Therapeutic contributions that improve epigenetic regulation of EMT will translate the clinical manifestation as treating cancer progression more efficiently.
- 27 November 2020
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11
Open AccessTackle Epithelial-Mesenchymal Transition With Epigenetic Drugs in Cancer
Epithelial-mesenchymal Transition (EMT) is a de-differentiation process in which epithelial cells lose their epithelial properties to acquire mesenchymal features. EMT is essential for embryogenesis and wound healing but is aberrantly activated in pathological conditions like fibrosis and cancer. Tumor-associated EMT contributes to cancer cell initiation, invasion, metastasis, drug resistance and recurrence. This dynamic and reversible event is governed by EMT-transcription factors (EMT-TFs) with epigenetic complexes. In this review, we discuss recent advances regarding the mechanisms that modulate EMT in the context of epigenetic regulation, with emphasis on epigenetic drugs, such as DNA demethylating reagents, inhibitors of histone modifiers and non-coding RNA medication. Therapeutic contributions that improve epigenetic regulation of EMT will translate the clinical manifestation as treating cancer progression more efficiently.